据Centocor公司(美国的一家生物技术公司)报道,该公司研究出一种在心肌梗塞形成后能快速鉴别心坏死和局部缺血的放射性标记的单克隆抗体,这可以改善心脏病患者的预后。该抗体叫作Myoscint,它选择了细胞内心肌成分肌浆球蛋白的重链,该肌浆球蛋白是在心脏病发怍后胞膜破裂时暴露出来的。因此,铟-Ⅲ标记的Myoscint可排它性地凝结在心坏死细胞上,用一种普通γ-射线照相机即可获得这些影像。在心肌梗塞形成初起注射该抗体后 According to Centocor, a biotech company in the United States, the company has developed a radio-labeled monoclonal antibody that rapidly identifies cardiac necrosis and ischemia after myocardial infarction, which can improve the prognosis of patients with heart disease. The antibody, called Myoscint, selects the heavy chain of the intramyocardial component myosin, which is exposed after the cell membrane ruptures after a heart attack. Therefore, Indium-III labeled Myoscint can exclusively coagulate on necrotic cells, using an ordinary gamma-ray camera. After the initial formation of myocardial infarction injection of the antibody